This medicine contains an active component Sevelamer Carbonate. This active ingredient is a phosphate binder. It prevents hypocalcemia induced by elevated phosphorus. It is used to control phosphorus levels in people with chronic kidney disease who are on dialysis. It also reduces serum phosphate concentrations without changing calcium, aluminum, or bicarbonate concentrations
Given medication is a phosphate binder that helps prevent hypocalcemia i.e. low levels of calcium in the body occurred by elevated phosphorus. Renvela controls phosphorus levels in people with chronic kidney disease who are on dialysis. This medicine is approved to lower high blood phosphorus levels in people who are on dialysis due to severe kidney disease. Dialysis helps remove some phosphate from the blood, but it is difficult to remove enough to keep phosphate levels balanced. Reducing blood phosphate levels can help keep bones strong, prevent unsafe buildup of minerals in the body, and possibly reduce the risk of heart disease and strokes that can result from high phosphate levels. It holds onto phosphate from the diet so that it can pass out of the body.
- Upper abdominal pain
- Mycophenolate mofetil
This mentioned medicine has active medicine sevelamer carbonate, which is a non-absorbed phosphate binder. It is a crosslinked polymer, free of metal and calcium that works by binding phosphate in the gastrointestinal tract and reducing absorption, Renvela carbonate decreases the phosphate concentration in the serum.
- This medicine is made available in a dosage as given below:
- 800 mg: It must be taken orally 3 times a day with meals as directed by the doctor
- Do not take any other medications within 1 hour before or 3 hours after consuming this drug. It can bind to other drugs and make them less effective.